ライフサイエンスコーパス: pyruvate dehydrogenase

1 , MCAT (malonylCoA:ACP transferase) and PDH (pyruvate dehydrogenase).

2 of other lipoic acid requiring enzymes (e.g. pyruvate dehydrogenase).

3 expression and inhibitory phosphorylation of pyruvate dehydrogenase.

4 r growth in PMN included the upregulation of pyruvate dehydrogenase.

5 buted to inhibition of the regulatory enzyme pyruvate dehydrogenase.

6 and acrylate pathways as well as a role for pyruvate dehydrogenase.

7 hyl acetylphosphonate, a potent inhibitor of pyruvate dehydrogenase.

8 iety from octanoyl-GcvH to the E2 subunit of pyruvate dehydrogenase.

9 se, thereby inhibiting glucose oxidation via pyruvate dehydrogenase.

10 eavy chain (MHC)-PDK4 mice), an inhibitor of pyruvate dehydrogenase.

11 increased phosphorylation and inhibition of pyruvate dehydrogenase.

12 nase 4 (PDK4), an inhibitor of mitochondrial pyruvate dehydrogenase.

13 dent regulation of the key metabolic enzyme, pyruvate dehydrogenase.

14 he p.E379K variant also has a de novo VUS in pyruvate dehydrogenase 1 (PDHA1) affecting the same amin

15 eam metabolism of [1-(13)C]pyruvate via PDH (pyruvate dehydrogenase, [(13)C]bicarbonate), lactate deh

16 omplexes carrying lipoic acid as a cofactor (pyruvate dehydrogenase, 2-oxoglutarate dehydrogenase and

17 In addition, pyruvate dehydrogenase, 2-oxoxglutarate dehydrogenase, a

18 chondrial calcium ([Ca(2+)]mito), inhibiting pyruvate dehydrogenase activity and glucose oxidation, w

19 PDK-mediated decreases in pyruvate dehydrogenase activity and oxygen consumption r

20 lycolysis, tricarboxylic acid metabolism and pyruvate dehydrogenase activity for ATP-dependent thermo

21 PDK3 was the principal kinase regulating pyruvate dehydrogenase activity in kidney and brain.

22 ports the previously indicated importance of pyruvate dehydrogenase activity in producing NADH during

23 In contrast, pyruvate dehydrogenase activity is significantly decreas

24 These results were consistent with the lower pyruvate dehydrogenase activity observed in children wit

25 hydrogenase phosphatase 1 (Pdp1) expression, pyruvate dehydrogenase activity, and glucose flux to the

26 ative function, increases in ATP content and pyruvate dehydrogenase activity, and marked inhibition o

27 e gastrocnemius muscle, oxfenicine increased pyruvate dehydrogenase activity, membrane GLUT4 content,

28 iated attenuation was sufficient to increase pyruvate dehydrogenase activity, oxidative phosphorylati

29 palmitate oxidation and increased indices of pyruvate dehydrogenase activity, TCA cycle flux, and hep

30 g II and PE, resulting in a reduction in the pyruvate dehydrogenase activity, the rate-limiting step

31 of multiple key enzyme complexes, including pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenas

32 -ketoacid dehydrogenase complexes, including pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenas

33 nsfer results in enhanced phosphorylation of pyruvate dehydrogenase and activation of AMPK, which act

34 dative damage to the lipoic acid cofactor of pyruvate dehydrogenase and alpha-ketoglutarate dehydroge

35 ell characterized as the E3 component of the pyruvate dehydrogenase and alpha-ketoglutarate dehydroge

36 the disruption of two key TCA cycle enzymes, pyruvate dehydrogenase and alpha-ketoglutarate dehydroge

37 itochondrial metabolism, enhancing oxidative pyruvate dehydrogenase and anaplerotic pyruvate carboxyl

38 n of two other genes isolated in the screen, pyruvate dehydrogenase and citrate synthase.

39 ntially druggable microbial factors, such as pyruvate dehydrogenase and ClpB, to help combat this ant

40 asing hepatic mitochondrial activity through pyruvate dehydrogenase and elevating enterohepatic bile

41 As a result, HAX-1 ablation activates pyruvate dehydrogenase and increases mitochondria utiliz

42 he ductal smooth muscle cells that activates pyruvate dehydrogenase and increases mitochondrial H2O2

43 te dehydrogenase kinase 1, which interrupted pyruvate dehydrogenase and reduced mitochondrial glucose

44 in late pregnancy lead to inhibition of PDH (pyruvate dehydrogenase) and pyruvate flux into the trica

45 r heat shock protein (HSP)-27, vimentin, and pyruvate dehydrogenase beta (PDHB), with a statistical s

46 Pharmacological inhibition of pyruvate dehydrogenase by triphenylbismuthdichloride was

47 ct of its activity, the inactive form of the pyruvate dehydrogenase complex (P-Pdc), both of which ar

48 increasing CHO oxidation in vivo, using the pyruvate dehydrogenase complex (PDC) activator, dichloro

49 w that all the subunits of the mitochondrial pyruvate dehydrogenase complex (PDC) are also present an

50 yl-CoA acetyltransferase 1 (ACAT1) regulates pyruvate dehydrogenase complex (PDC) by acetylating pyru

51 The pyruvate dehydrogenase complex (PDC) catalyzes the conve

52 The human pyruvate dehydrogenase complex (PDC) comprises four mult

53 ogenase (PDH) and consequently inhibition of pyruvate dehydrogenase complex (PDC) in cancer cells.

54 The pyruvate dehydrogenase complex (PDC) is a critical mitoc

55 Mammalian pyruvate dehydrogenase complex (PDC) is a key multi-enzy

56 The pyruvate dehydrogenase complex (PDC) is a multienzyme as

57 Mitochondrial pyruvate dehydrogenase complex (PDC) is crucial for gluc

58 The mitochondrial pyruvate dehydrogenase complex (PDC) is down-regulated b

59 The pyruvate dehydrogenase complex (PDC) is the primary meta

60 The mitochondrial pyruvate dehydrogenase complex (PDC) plays a crucial rol

61 High-fat feeding inhibits pyruvate dehydrogenase complex (PDC)-controlled carbohyd

62 etyl-CoA in mitochondria is catalyzed by the pyruvate dehydrogenase complex (PDC).

63 activates mitochondrial PDH and consequently pyruvate dehydrogenase complex (PDC).

64 AT5A bound the E1beta and E2 subunits of the pyruvate dehydrogenase complex (PDC).

65 hondrial response to the E2 component of the pyruvate dehydrogenase complex (PDC-E2), has unique feat

66 ecular mimicry between the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), the major mitoc

67 ondrial autoantigen, the E2 component of the pyruvate dehydrogenase complex (PDC-E2).

68 The pyruvate dehydrogenase complex (PDH) critically regulate

69 The pyruvate dehydrogenase complex (PDH) has been hypothesiz

70 the metabolic consequence of activating the pyruvate dehydrogenase complex (PDH) to increase pyruvat

71 as a cellular lipoamidase that regulates the pyruvate dehydrogenase complex (PDH).

72 xidative decarboxylation of pyruvate via the pyruvate dehydrogenase complex (PDH).

73 activated in mouse metastasis models, drives pyruvate dehydrogenase complex (PDHc) activation to main

74 In Escherichia coli, the pyruvate dehydrogenase complex (PDHC) and pyruvate forma

75 The Escherichia coli pyruvate dehydrogenase complex (PDHc) catalyzing convers

76 cherichia coli and report that disruption of pyruvate dehydrogenase complex (PDHc), which converts py

77 tabolic fuel selection as a component of the pyruvate dehydrogenase complex (PDHc).

78 f oxidative phosphorylation by targeting the pyruvate dehydrogenase complex (PDHC).

79 At baseline, IMTG, muscle pyruvate dehydrogenase complex activity and the protein

80 et-induced obese mice significantly augments pyruvate dehydrogenase complex activity with reduced pho

81 45 and 392 on PDHK2 and results in increased pyruvate dehydrogenase complex activity.

82 oduction via glucose oxidation by depressing pyruvate dehydrogenase complex activity.

83 ase-specific loss of immune tolerance to the pyruvate dehydrogenase complex and subsequent developmen

84 rotein complexes identified in our analysis, pyruvate dehydrogenase complex and succinate dehydrogena

85 e of oxythiamine, which can inhibit both the pyruvate dehydrogenase complex and transketolase, result

86 l analysis showing that the lipoyl moiety of pyruvate dehydrogenase complex appears to be involved in

87 ively regulate activity of the mitochondrial pyruvate dehydrogenase complex by reversible phosphoryla

88 e two active centers of the Escherichia coli pyruvate dehydrogenase complex E1 component provides a s

89 The PKCdelta/retinol complex signaled the pyruvate dehydrogenase complex for enhanced flux of pyru

90 s (HiBECs) translocate the E2 subunit of the pyruvate dehydrogenase complex immunologically intact in

91 ainst a complex set of proteins, among which pyruvate dehydrogenase complex is considered the main au

92 t indicates that inhibition of the bacterial pyruvate dehydrogenase complex may represent a promising

93 Possible interactions between CfrA and the pyruvate dehydrogenase complex or PII protein have been

94 drogenase kinase 4 (PDK4) is upregulated and pyruvate dehydrogenase complex phosphorylation is increa

95 he E3-binding domain (E3BD) of the mammalian pyruvate dehydrogenase complex show that hSBDb has an ar

96 ese novel genetic interactions involving the pyruvate dehydrogenase complex suggested a new role for

97 umor activity is its ability to activate the pyruvate dehydrogenase complex through inhibition of pyr

98 e that loss of PDHK4, a key regulator of the pyruvate dehydrogenase complex, caused a profound cell g

99 f pdhD, putatively encoding a subunit of the pyruvate dehydrogenase complex, impairs survival of both

100 e investigated whether the E2 subunit of the pyruvate dehydrogenase complex, the E2 subunit of the br

101 dehydrogenase kinase 2 (PDHK2) inhibits the pyruvate dehydrogenase complex, thereby regulating entry

102 ion of the E1alpha regulatory subunit of the pyruvate dehydrogenase complex, which in turn inhibits f

103 kinase 1 (PDK1) on Thr346 to inactivate the pyruvate dehydrogenase complex.

104 PDH2, which encodes a subunit of the plastid pyruvate dehydrogenase complex.

105 at may catalyze the dephosphorylation of the pyruvate dehydrogenase complex.

106 nt, uncompetitive inhibitor of the bacterial pyruvate dehydrogenase complex.

107 ologic phenotypes, or PDHX, a subunit of the pyruvate dehydrogenase complex.

108 sion of pyruvate to acetyl-coenzyme A by the pyruvate dehydrogenase complex.

109 The pyruvate dehydrogenase complexes (PDCs) from all known l

110 Most bacterial pyruvate dehydrogenase complexes from either gram-positi

111 A key target of MGF appears to be pyruvate dehydrogenase, determined to be activated by MG

112 y E2 subunits of branched chain ketoacid and pyruvate dehydrogenases during lipoate scavenging.

113 However, induction of the expressions of the pyruvate dehydrogenase E1 component subunit beta (PDHB)

114 ing protein C), glucose metabolism proteins (pyruvate dehydrogenase E1, PYGB, Pgm2), and antioxidant

115 bstrate YHGH(292)SMSDPGSTYR derived from the pyruvate dehydrogenase E1alpha subunit sequence.

116 inducible inhibitory phosphorylations on the pyruvate dehydrogenase E1alpha subunit.

117 e E2 subunit of the metabolic enzyme complex pyruvate dehydrogenase (E2-PDH) with a fatty acid deriva

118 They had low pyruvate dehydrogenase enzyme activity but most did not

119 nase 1 (PDK1) protein levels and a decreased pyruvate dehydrogenase enzyme activity.

120 herapeutic levels in the RV, reduced phospho-pyruvate dehydrogenase expression, RV fibrosis, and hype

121 In fed rats, Acipimox decreased pyruvate dehydrogenase flux (to 0.512 +/- 0.13, P = .04)

122 overload caused heart failure with decreased pyruvate dehydrogenase flux and poor ejection fraction r

123 vestigate the rate and regulation of in vivo pyruvate dehydrogenase flux in the hyperthyroid heart an

124 9, P = .002), though this rise did not match pyruvate dehydrogenase flux observed in rats fed carbohy

125 , (2) rats in which dichloroacetate enhanced pyruvate dehydrogenase flux, and (3) rats in which dobut

126 In vivo pyruvate dehydrogenase flux, assessed with hyperpolarize

127 By 22 weeks, alterations were also seen in pyruvate dehydrogenase flux, which decreased at lower ej

128 (13)CO2:[1-(13)C]pyruvate ratio, an index of pyruvate dehydrogenase flux.

129 e changes were independent of alterations in pyruvate dehydrogenase flux.

130 Krebs cycle activity precede a reduction in pyruvate dehydrogenase flux.

131 his hypothesis we assessed relative rates of pyruvate dehydrogenase flux/mitochondrial oxidative flux

132 3-bp GCT nonframeshift insertion in the pdhA pyruvate dehydrogenase gene were detected in the oxacill

133 the key molecular substitution in duplicated pyruvate dehydrogenase genes that underpins one of the m

134 es new support for the presence of an active pyruvate dehydrogenase in this stage.

135 tion in activated MPs, resulting in regional pyruvate dehydrogenase inhibition.

136 that metabolism of pyruvate by both LDH and pyruvate dehydrogenase is subject to the acute effects o

137 In humans, the enzyme pyruvate dehydrogenase is transiently nuclear at the 4/8

138 (off-rate, kd) for compounds binding to the pyruvate dehydrogenase kinase (PDHK) enzyme.

139 ylation activates and inhibits mitochondrial pyruvate dehydrogenase kinase (PDK) and phosphatase (PDP

140 od development, we used the dedicated kinase pyruvate dehydrogenase kinase (PDK) for the in vitro ass

141 Treatment of endometriosis HPMCs with the pyruvate dehydrogenase kinase (PDK) inhibitor/PDH activa

142 wn-regulated by phosphorylation catalyzed by pyruvate dehydrogenase kinase (PDK) isoforms 1-4.

143 acetic acids are developed for inhibition of pyruvate dehydrogenase kinase (PDK), an enzyme responsib

144 by inhibiting a key enzyme in cancer cells, pyruvate dehydrogenase kinase (PDK), that is required fo

145 Here, we show that pyruvate dehydrogenase kinase (PDK)-2 plays a role in hy

146 lation governed by at least four isozymes of pyruvate dehydrogenase kinase (PDK).

147 Pyruvate dehydrogenase kinase (PDK)4, a critical regulat

148 report that hypoxia drives expression of the pyruvate dehydrogenase kinase (PDK1) and EGFR along with

149 We observed increased expression of pyruvate dehydrogenase kinase 1 (a HIF gene target), whi

150 K1 acts as a protein kinase to phosphorylate pyruvate dehydrogenase kinase 1 (PDHK1) at T338, which a

151 lysis in part due to increased expression of pyruvate dehydrogenase kinase 1 (PDK1) and lactate dehyd

152 We identify pyruvate dehydrogenase kinase 1 (PDK1) as an important d

153 Here, we show that pyruvate dehydrogenase kinase 1 (PDK1) is enriched in br

154 tochondria during hypoxia and phosphorylates pyruvate dehydrogenase kinase 1 (PDK1) on Thr346 to inac

155 ycolysis, which were paralleled by increased pyruvate dehydrogenase kinase 1 (PDK1) protein levels an

156 result in the induction of the gene encoding pyruvate dehydrogenase kinase 1 (PDK1), which inhibits p

157 gulation of key glycolytic enzymes including pyruvate dehydrogenase kinase 1 (PDK1).

158 ascular endothelial growth factor (VEGF) and pyruvate dehydrogenase kinase 1 (PDK1).

159 n HP [1-(13)C]lactate was likely mediated by pyruvate dehydrogenase kinase 1 up-regulation in activat

160 athways and dephosphorylates and inactivates pyruvate dehydrogenase kinase 1, Akt, Raf, mitogen-activ

161 nsporter Glut1, phospho-fructose kinase, and pyruvate dehydrogenase kinase 1, which interrupted pyruv

162 Pyruvate dehydrogenase kinase 2 (PDHK2) inhibits the pyr

163 Compared with CD, HFD increased resting pyruvate dehydrogenase kinase 2 (PDK2), PDK4, forkhead b

164 f PKCdelta leads to the dephosphorylation of pyruvate dehydrogenase kinase 2 (PDK2), thereby decreasi

165 cle glucose metabolism in awake mice lacking pyruvate dehydrogenase kinase 2 and 4 [double knockout (

166 mice with cardiac-specific overexpression of pyruvate dehydrogenase kinase 4 (myosin heavy chain (MHC

167 ibility is driven by robust up-regulation of pyruvate dehydrogenase kinase 4 (PDK4) and phosphorylati

168 A splice site mutation in the canine pyruvate dehydrogenase kinase 4 (PDK4) gene has been sho

169 sion and uncovered an enhanced expression of pyruvate dehydrogenase kinase 4 (PDK4) in the Glyco(Hi)

170 In this study, we have observed that pyruvate dehydrogenase kinase 4 (PDK4) is upregulated an

171 Furthermore, Dex suppressed LPS-induced pyruvate dehydrogenase kinase 4 (PDK4) mRNA upregulation

172 Knockdown of pyruvate dehydrogenase kinase 4 (PDK4) or inhibition wit

173 tin-like 4 (ANGPTL4)-induced upregulation of pyruvate dehydrogenase kinase 4 (PDK4), an inhibitor of

174 for carnitine palmitoyltransferase (cpt1a), pyruvate dehydrogenase kinase 4 (pdk4), and phosphoenolp

175 the downregulation of a miR-211 target gene, pyruvate dehydrogenase kinase 4 (PDK4).

176 thalamic expression of four genes, including pyruvate dehydrogenase kinase 4 and glycerol 3-phosphate

177 activated receptor-gamma coactivator-1alpha, pyruvate dehydrogenase kinase 4 and mitochondrial transc

178 Cardiac pyruvate dehydrogenase kinase 4 expression was upregulat

179 ose oxidation was mediated by a reduction in pyruvate dehydrogenase kinase 4 expression, enabling pyr

180 protein and glycogen content, and increased pyruvate dehydrogenase kinase 4 mRNA abundance in the he

181 Pyruvate dehydrogenase kinase 4 upregulation correlated

182 pregnancy hormone progesterone induces PDK4 (pyruvate dehydrogenase kinase 4) in cardiomyocytes and t

183 blastoma protein-E2F-induced upregulation of pyruvate dehydrogenase kinase 4, and targeting these pat

184 ctivity still remains its ability to inhibit pyruvate dehydrogenase kinase and force mitochondrial ox

185 calization of the aerobic glycolysis enzymes pyruvate dehydrogenase kinase and lactate dehydrogenase

186 Our results show that pyruvate dehydrogenase kinase inhibition improves the co

187 roduction, as glycolytic inhibition with the pyruvate dehydrogenase kinase inhibitor dichloroacetate

188 long-term delivery of dichloroacetic acid, a pyruvate dehydrogenase kinase inhibitor.

189 Deltaex3/Bnip3FL isoform ratio by inhibiting pyruvate dehydrogenase kinase isoform 2 (PDK2) in Panc-1

190 Pyruvate dehydrogenase kinase isoform 2 (PDK2) was ident

191 Pyruvate dehydrogenase kinase isoforms (PDKs 1-4) negati

192 ivation of phosphoinositide 3-kinase (PI3K), pyruvate dehydrogenase kinase isozyme 1 (PDK1), and mamm

193 gulation of the gene expression response for pyruvate dehydrogenase kinase to pressure overload.

194 s to glucose oxidation, via an inhibition of pyruvate dehydrogenase kinase was used.

195 g water containing no supplement or the PDK (pyruvate dehydrogenase kinase) inhibitor dichloroacetate

196 O1-mediated transcriptional upregulation of pyruvate dehydrogenase kinase), and glutaminolysis (refl

197 es PDHc activity by altering the affinity of pyruvate dehydrogenase kinase, an inhibitor of the enzym

198 enzyme biosynthesis and iron metabolism, the pyruvate dehydrogenase kinase, and a type 2C protein pho

199 tal RVH and can be achieved by inhibition of pyruvate dehydrogenase kinase, fatty acid oxidation, or

200 thyroidism increases the ex vivo activity of pyruvate dehydrogenase kinase, thereby inhibiting glucos

201 HIF-1alpha increased glycolytic enzymes and pyruvate dehydrogenase kinase-1 (PDK-1), which reduces m

202 lucose transporters, glycolytic enzymes, and pyruvate dehydrogenase kinase-1 were increased in their

203 ctivity, because specific inhibition of Akt, pyruvate dehydrogenase kinase-1, or its downstream targe

204 led to the upregulation of the HIF1 target, pyruvate dehydrogenase kinase-1, which inhibits PDH acti

205 th factor (VEGF), glucose transporter-1, and pyruvate dehydrogenase kinase-1.

206 Wild-type p53 expression decreased levels of pyruvate dehydrogenase kinase-2 (Pdk2) and the product o

207 vates the PI3K/Akt-STAT3 pathway, leading to pyruvate dehydrogenase kinase-2 (PDK2) upregulation and

208 via specific reduction in the expression of pyruvate dehydrogenase kinase-3 (PDK3).

209 DH inhibitory phosphorylation, expression of pyruvate dehydrogenase kinase-3, and levels of hypoxia i

210 protein O1 (FOXO1) mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) gene transcriptio

211 of histone deacetylase, cyclooxygenase, and pyruvate dehydrogenase kinase.

212 he hyperthyroid heart in vivo is mediated by pyruvate dehydrogenase kinase.

213 dehydrogenase complex through inhibition of pyruvate dehydrogenase kinase.

214 PDC is inhibited by phosphorylation via the pyruvate dehydrogenase kinases (PDKs).

215 e mitochondria by increasing the activity of pyruvate dehydrogenase kinases 1 and 4.

216 Phosphorylation of PDH by one of the pyruvate dehydrogenase kinases 1-4 (PDK1-4) decreases th

217 2 released specifically from mitochondria by pyruvate dehydrogenase-mediated metabolism of hyperpolar

218 phenyl)-1,1-dimethylurea and antimycin A, of pyruvate dehydrogenase, moniliformin, of calmodulins, N-

219 and E1 components from the Escherichia coli pyruvate dehydrogenase multienzyme complex (PDHc), as a

220 The Escherichia coli pyruvate dehydrogenase multienzyme complex (PDHc), consi

221 The Escherichia coli pyruvate dehydrogenase multienzyme complex contains mult

222 have provided additional gene copies of the pyruvate dehydrogenase multienzyme complex that have evo

223 E.g. pyruvate dehydrogenase mutants accumulated large amounts

224 o-ADP ratio) by hypoxia, or by inhibitors of pyruvate dehydrogenase or electron transport chain compl

225 ainst the lipoyl domain of the E2 subunit of pyruvate dehydrogenase (PDC-E2) are detected in 95% of p

226 ly restricted peptide of the E2 component of pyruvate dehydrogenase (PDC-E2) involving autoantibody a

227 ainst the lipoyl domain of the E2 subunit of pyruvate dehydrogenase (PDC-E2).

228 Phosphorylated pyruvate dehydrogenase (PDH) (Ser-293) and PDH kinase 4

229 tably, the siblings' fibroblasts had reduced pyruvate dehydrogenase (PDH) activity and elevated intra

230 As pyruvate dehydrogenase (PDH) activity appears central to

231 Levels of both glutamate and pyruvate dehydrogenase (PDH) activity have been shown to

232 s network of genes also causes inhibition of pyruvate dehydrogenase (PDH) activity resulting in dimin

233 muscle, which was associated with decreased pyruvate dehydrogenase (PDH) activity, accumulation of p

234 points after injury, in line with decreased pyruvate dehydrogenase (PDH) activity, suggesting impair

235 oA in the TAZ-KO cells to a ~50% decrease in pyruvate dehydrogenase (PDH) activity, which was observe

236 nhanced inhibitory serine phosphorylation of pyruvate dehydrogenase (PDH) and consequently inhibition

237 e dehydrogenase complex (PDC) by acetylating pyruvate dehydrogenase (PDH) and PDH phosphatase.

238 e on glutaminolysis through malic enzyme and pyruvate dehydrogenase (PDH) as well as fatty acid and b

239 A Pyruvate dehydrogenase (PDH) assay mechanistically confi

240 nvolves inhibitory serine phosphorylation of pyruvate dehydrogenase (PDH) by PDH kinase (PDK), wherea

241 Mechanistically, silencing MICU1 activates pyruvate dehydrogenase (PDH) by stimulating the PDPhosph

242 The mitochondrial pyruvate dehydrogenase (PDH) complex (PDC) acts as a cen

243 nverting pyruvate to acetyl-CoA (AcCoA), the pyruvate dehydrogenase (PDH) complex (PDC) links glycoly

244 The pyruvate dehydrogenase (PDH) complex connects the glycol

245 untington's disease (HD) by showing that the pyruvate dehydrogenase (PDH) complex is a promising ther

246 P. falciparum possesses a pyruvate dehydrogenase (PDH) complex that is localized t

247 Resveratrol targets the pyruvate dehydrogenase (PDH) complex, a key mitochondria

248 vates PDHK1 to phosphorylate and inhibit the pyruvate dehydrogenase (PDH) complex.

249 encoding the E2 subunit of the mitochondrial pyruvate dehydrogenase (PDH) complex.

250 d-chain 2-oxoacid dehydrogenase (BCKDH), and pyruvate dehydrogenase (PDH) complexes are also capable

251 We define a pyruvate dehydrogenase (PDH) dependency in leader cells

252 es in mitochondrial bioenergetics, including pyruvate dehydrogenase (PDH) dysfunction, have been desc

253 ation in skeletal muscle is due to decreased pyruvate dehydrogenase (PDH) enzyme activity related, in

254 ummary Plasmodium parasites possess a single pyruvate dehydrogenase (PDH) enzyme complex that is loca

255 Plasmodium parasites possess a single pyruvate dehydrogenase (PDH) enzyme complex that is loca

256 In four groups of eight Wistar rats, we used pyruvate dehydrogenase (PDH) flux studies to demonstrate

257 atory macrophages reroute pyruvate away from pyruvate dehydrogenase (PDH) in an NO-dependent and hypo

258 Metabolic profiling revealed that pyruvate dehydrogenase (PDH) is a key bifurcation point

259 However, flux through pyruvate dehydrogenase (PDH) is disproportionally decrea

260 Pyruvate dehydrogenase (PDH) is the main regulator of th

261 by, in part, upregulating gene expression of pyruvate dehydrogenase (PDH) kinase 1 (PDHK1), which pho

262 bolic reprogramming by markedly upregulating pyruvate dehydrogenase (PDH) kinase 4 (PDK4) through est

263 a-oxidation-derived NADH, which can activate pyruvate dehydrogenase (PDH) kinase isoforms that inhibi

264 Intralipid enhanced pyruvate dehydrogenase (PDH) phosphorylation and lactate

265 Pyruvate dehydrogenase (PDH) plays a well-known metaboli

266 stress-induced inhibitory phosphorylation of pyruvate dehydrogenase (PDH) that impaired the routing o

267 ehydrogenase kinase 1 (PDK1), which inhibits pyruvate dehydrogenase (PDH) via phosphorylation.

268 DP/ATP carrier protein (AAC) 1 and AAC2, and pyruvate dehydrogenase (PDH) were assessed by respiromet

269 ochondrial biogenesis and phosphorylation of pyruvate dehydrogenase (PDH) were observed in kidneys fr

270 and phosphorylation-dependent inhibition of pyruvate dehydrogenase (PDH) within a single day of feed

271 ral essential multienzyme complexes, such as pyruvate dehydrogenase (PDH), alpha-ketoglutarate dehydr

272 respiration, decreased enzymatic activity of pyruvate dehydrogenase (PDH), and increased production o

273 pyruvate dehydrogenase phosphatase (PDP) and pyruvate dehydrogenase (PDH), dramatically increased PDH

274 outes for carbohydrate oxidation, other than pyruvate dehydrogenase (PDH), in hypertrophied heart.

275 Inactivation of aceE, a subunit of pyruvate dehydrogenase (PDH), was found to increase leve

276 elta is synthetically lethal with mutants in pyruvate dehydrogenase (PDH), which catalyzes the conver

277 in AML cells increased nuclear pyruvate and pyruvate dehydrogenase (PDH), which induced histone acet

278 In muscle, adropin activates pyruvate dehydrogenase (PDH), which is rate limiting for

279 s through dephosphorylation or activation of pyruvate dehydrogenase (PDH), which mediates opening of

280 ivity of the most important enzyme component pyruvate dehydrogenase (PDH).

281 r determinants (glycolysis, gluconeogenesis, pyruvate dehydrogenase [PDH], and H2O2 levels) in mice s

282 te decarboxylase (AceE), the E1 component of pyruvate dehydrogenase (PDHC), can participate in AceE/D

283 Representatively, the bacterial pyruvate dehydrogenase (PdhR), trehalose (TreR), and l-a

284 proliferation, altered expression levels of pyruvate dehydrogenase phosphatase (PDP) and pyruvate de

285 mponents and by NOTCH-dependent induction of pyruvate dehydrogenase phosphatase 1 (Pdp1) expression,

286 with suppression of the catalytic subunit of pyruvate dehydrogenase phosphatase 1 this leads to incre

287 5, glucose transporter GLUT2, phosphorylated pyruvate dehydrogenase pPDH and PDH-kinase.

288 [(13)C]O3(-) appearance reflects activity of pyruvate dehydrogenase rather than pyruvate carboxylatio

289 glyceraldehyde 3-phosphate dehydrogenase and pyruvate dehydrogenase subunit e1alpha.

290 mic functions, include GroEL, DnaK, enolase, pyruvate dehydrogenase subunits PdhB and PdhD, and SodA.

291 bited hyperphosphorylation and inhibition of pyruvate dehydrogenase, the key Ca(2+)-sensitive gatekee

292 channeling of mitochondrial acetyl-CoA from pyruvate dehydrogenase to carnitine acetyltransferase.

293 dehydrogenase kinase 4 expression, enabling pyruvate dehydrogenase to compete against anaplerotic en

294 nt ones, such as Streptococcus gordonii, use pyruvate dehydrogenase to decarboxylate pyruvate.

295 basal and insulin-stimulated rates of muscle pyruvate dehydrogenase (VPDH) flux relative to citrate s

296 tric acid cycle (as inferred by flux through pyruvate dehydrogenase), were down-regulated by beta-lap

297 Pharmacologic inhibitor of pyruvate dehydrogenase, which controls the transition fr

298 The complex control of pyruvate dehydrogenase, which links glycolysis to the TC

299 regulation and subsequent phosphorylation of pyruvate dehydrogenase, which results in reduction in py

300 establish whether modulation of flux through pyruvate dehydrogenase would alter cardiac hypertrophy.